ShiftBio

03/11/2025

We are thrilled and honored to share that our CEO, Prof. Gihoon Nam, was an invited speaker at Dassault Systèmes’ Science Week 2025 in Boston! 🎤🌟

During his talk, Prof. Nam showcased the progress of our AI-driven drug-delivery platform, developed on Dassault’s 3DEXPERIENCE through a powerful three-year collaboration with BIOVIA. He also shared our broader vision to leverage Dassault’s Virtual Twin Experience across the entire drug-development lifecycle, from discovery and CMC to clinical studies and final approval.

To make this vision a reality, ShiftBio is expanding our foundational partnership with Dassault Systèmes and deepening our collaboration with the BIOVIA Research Team to overcome the delivery void with our platform.

Our ultimate goal is to become a flagship reference, a small biotech that fully embraces the power of the 3DEXPERIENCE ecosystem, seamlessly connecting the virtual and real worlds from discovery through full development.

This vision reflects our shared belief that digital AI and simulation are no longer optional: they are essential to meaningful innovation. 🚀

31/10/2025

Celebrating Science, Collaboration, and Innovation!

At the 2025 DIPS Global Tech Con, Dr. Yoonjeong Choi represented SHIFTBIO, introducing our AI-Driven Natural Drug Delivery Platform — a next-generation technology that merges biological insight with digital intelligence.

Together with distinguished experts, she explored how AI can accelerate drug development and how global collaboration can fuel the next wave of biomedical innovation.

We’re excited to be part of this global movement shaping the future of therapeutics.

17/10/2025

We are thrilled to announce major momentum in our pipeline, driven by our proprietary Natural Drug Delivery Platform.

In oncology, we have successfully completed a Pre-IND meeting with the U.S. FDA for SBI-101, our novel candidate targeting PD-1 blockade resistant Cold Tumors. This marks a crucial step forward in addressing a major unmet need for cancer treatment.

Simultaneously, we are accelerating another program (SBI-102) toward clinical entry in Australia. We have partnered with a leading global CRO for our NNP-based candidate for inflammatory and autoimmune diseases. Building on its existing Orphan Drug Designation (ODD) from the FDA, our immediate next step is to submit our clinical trial application to the TGA.

These parallel advancements highlight the immense potential of our NNP platform to tackle challenging diseases. We are more committed than ever to progressing our therapies for patients around the globe!

For more details, please refer to below links
SBI-101: https://www.sciencedirect.com/science/article/pii/S016836592200637X
SBI-102: https://www.nature.com/articles/s41467-025-57133-w

Acute liver failure arises from rapid cell death and impaired liver regeneration. Here, the authors show that scalable, high-purity engineered extracellular vesicles derived from stem cells promote the clearance of dying hepatocytes and drive liver repair through in vivo macrophage reprogramming.

14/10/2025

It was an honor to be featured at Try Everything 2025, Seoul's iconic global festival where the future of technology and innovation is shaped. The event is a critical nexus for Korean startups to connect with the world and share their expansion journeys. For ShiftBio, an early member and past winner of the Korea Conference community, being invited back as a mentor to this pivotal gathering was a profound honor.

The mentorship and investment from this community have been a critical catalyst for our growth, providing a crucial foundation for achieving our company's key milestones. Now, we are applying our Natural drug delivery platform technology to tackle immense unmet needs in areas like CNS and Inflammation diseases. This journey would not be possible alone, and we remain committed to innovating for global health while supporting the next generation. We extend our sincere gratitude to the Seoul Metropolitan Government for hosting, with a special acknowledgment to Jenny Chu, the Korea Conference, and our dedicated colleagues for their unwavering support!

25/09/2025

SHIFTBIO CEO Gi-hoon Nam met with Pascal Daloz, CEO of Dassault Systèmes, and Woonsung Jung, Managing Director, Dassault Systèmes Korea, in Seoul to discuss deepening collaboration. Over the past three years, SHIFTBIO has actively applied Dassault’s 3DEXPERIENCE platform to accelerate the design and validation of our Natural Nanoparticle (NNP) drug delivery platform. This collaboration has reduced trial and error in discovery and strengthened our ability to translate science into real-world therapeutic opportunities.

At the meeting, both sides reaffirmed a shared vision of combining AI-powered design with digital platforms to de-risk the development of next-generation therapeutics. SHIFTBIO has also been invited to speak at Dassault’s upcoming Science in the Age of Experience event in Boston this October, engaging with global pharma leaders, regulators, and innovators.

Together, SHIFTBIO and Dassault aim to pioneer a new paradigm in advanced therapeutics, making innovation more accessible and impactful for patients worldwide!

Find out more about the event: https://lnkd.in/gC6Vet7g

08/08/2025

GEN Genetic Engineering & Biotechnology News has recognized SHIFTBIO as a leading innovator in EV-based drug delivery in the Asia-Pacific region. The article highlights how our NNP-Design AI™ platform and large-scale manufacturing capabilities are redefining the field.

Our lead program, SBI-102, harnesses macrophage reprogramming to target inflammatory diseases and is steadily progressing toward clinical entry. In parallel, we are advancing brain-targeted and inflammation-targeted delivery systems powered by our NNP-Design AI™ platform—opening new frontiers in precision medicine.

SHIFTBIO’s mission goes beyond research. We are building a future that delivers real, lasting impact for patients and society.

https://hubs.ly/Q03yKthd0

With greater investment to improve the scalability and consistency of manufacturing, EV-based medicine is poised to shape therapeutics delivery in the near future.

29/05/2025

🚀 MAKING THE IMPOSSIBLE POSSIBLE: Breakthrough Published in Biomaterials!

SHIFTBIO proudly announces groundbreaking research published in Biomaterials (IF 14.0+) - solving one of medicine's greatest challenges: turning unstable therapeutics into powerful, targeted treatments.

🎯 The Challenge We Solved: Apelin peptides showed promise for Pulmonary Arterial Hypertension (PAH) but vanished within hours in the bloodstream - until now.

⚡ Our Innovation: ✅ IFITM3-based EV platform - engineered for optimal C-terminal cargo display ✅ 24-hour plasma stability vs.

27/02/2025

시프트바이오가 첫 번째 신약 프로그램 연구 성과를 Nature Communications에 게재하며, 세포외소포(Extracellular Vesicle, EV) 기반 신약 개발의 가능성을 입증했습니다. 이번 연구에서는 ‘Dual-mode of action을 통한 In vivo 대식세포 리프로그래밍 기전’과 ‘고순도·고효율 EV 대량 생산 공정 확립’을 제시하며, 차세대 약물 전달 기술의 새로운 기준을 마련했습니다.

기사에서도 언급된 대로, 시프트바이오는 이번 연구 성과를 시작으로 세포 자체를 사용하지 않으면서도 기존 전달체 기술로는 도달할 수 없는 부위까지 약물을 전달하는 혁신적인 인비보(In vivo) 세포 치료제를 지속적으로 공개할 예정입니다.

신약 개발의 새로운 패러다임을 제시하고, 글로벌 바이오 시장에서 독보적인 기술력을 확보해 나갈 시프트바이오의 내일을 더욱 기대해 주시기 바랍니다. 감사합니다.

[의학신문·일간보사=오인규 기자] 시프트바이오는 첫 번째 신약 프로그램 연구 성과가 세계적 학술지인 네이처 커뮤니케이션스(Nature Communications)에 게재됐다고 26일 밝혔다.시프트바이오는 최근 자사 공식...

24/02/2025

(주) 시프트바이오의 주요 프로그램 관련 연구 성과가 Nature Communications에 게재되었습니다. 해당 연구는 차별화된 기술력과 혁신적 접근법을 통해 다음과 같은 주요 성과를 달성했습니다:

- Dual-mode of action을 통한 In vivo 대식세포 리프로그래밍 기전 설명
- 고품질 고순도 고효율 대규모 제조 공정 확립을 통한 상업적 생산을 위한 탁월한 확장 가능성을 입증

특히, 본 프로그램은 미국 FDA 희귀의약품 지정(Orphan Drug Designation, ODD)을 획득하며, 급성 간부전(Acute Liver Failure) 치료 분야에서 독보적인 혁신성과 높은 의학적 필요를 이미 인정받은 바 있습니다.

이번 성과는 SBI의 과학적 성숙도와 변혁적인 잠재력을 기반으로, 견고한 기술력과 임상적 가능성이 만나는 순간을 만들어내며, 신약 개발의 새로운 기준을 제시하고 있습니다.

SBI는 앞으로도 뛰어난 영향력을 통해 의료 패러다임의 변화를 선도할 것입니다. 이번 여정을 함께해 주신 헌신적인 팀원들과 소중한 협력사들께 진심으로 감사의 인사를 전합니다.

Acute liver failure arises from rapid cell death and impaired liver regeneration. Here, the authors show that scalable, high-purity engineered extracellular vesicles derived from stem cells promote the clearance of dying hepatocytes and drive liver repair through in vivo macrophage reprogramming.

17/12/2024

“세상에서 가장 특별한 인연”, ㈜시프트바이오와 함께하는 고마운 분들이 모여 송년의 밤 행사를 성료했습니다.

각자의 자리에서 하나의 목표를 향해 정진하는 서로를 격려하고 축하하며, 2024년을 마무리하고 2025년을 준비했습니다.

물론 대외적인 성과도 많았지만,
올해는 ㈜시프트바이오가 내부 팀 제도를 재정비하고, 콘테스트를 통해 아이디어를 모으는 등 내실과 기반을 다지는 데에도 집중했습니다. 그 결실들이 앞으로 더 큰 성과와 발전으로 맺어질 것이라 기대됩니다.

항상 신뢰와 격려로 지켜봐주시는 모든 분들께 감사드리며, 새해에도 더욱 정진하는 ㈜시프트바이오의 모습 보여드리겠습니다. 감사합니다.

12/12/2024

지난 12월 9일 개최된 '2024년 글로벌 기업 협업 프로그램-성과공유회 및 기술포럼‘ 행사에서 ㈜시프트바이오가 글로벌 협업 우수기업으로 선정, 수상과 함께 성과 발표를 진행했습니다.

2024년 한 해 동안 (주)시프트바이오는 세계 경제 불확실성 속에서도 꾸준한 연구와 성과를 지속하며, 탄탄한 투자 기반을 다져왔습니다. 항상 신뢰와 응원으로 함께해 주신 모든 분들께 감사드립니다. 2025년에도 더욱 노력하여 성과로 보답드리겠습니다.

18/11/2024

지난 11월 13일, ㈜시프트바이오 본사에 루스터바이오 임직원들이 방문했습니다.

줄기세포 및 세포외소포체 관련 대량생산 공정 개발 전문가인 글로벌 기업 루스터바이오는 ㈜시프트바이오와 3년 전부터 파트너십을 맺고 신약개발을 위해 함께 정진하고 있습니다.

이번에도 파트너십 강화 및 향후 프로젝트에 대한 아이디어 등을 논의하며 뜻깊은 시간을 함께했습니다. 향후 루스터바이오와 ㈜시프트바이오가 이뤄낼 의미 있는 성과에 많은 기대와 응원 부탁드립니다. 감사합니다.